CVE:CZO

Ceapro Competitors

C$0.72
-0.02 (-2.70 %)
(As of 04/20/2021 02:52 PM ET)
Add
Compare
Today's Range
C$0.72
Now: C$0.72
C$0.75
50-Day Range
C$0.63
MA: C$0.68
C$0.79
52-Week Range
C$0.24
Now: C$0.72
C$0.98
Volume19,276 shs
Average Volume60,615 shs
Market CapitalizationC$55.88 million
P/E Ratio21.82
Dividend YieldN/A
BetaN/A

Competitors

Ceapro (CVE:CZO) Vs. NVH, MBX, PDP, SBM, PMN, and COV

Should you be buying CZO stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Ceapro, including Novoheart (NVH), Microbix Biosystems (MBX), Pediapharm (PDP), Sirona Biochem (SBM), ProMIS Neurosciences (PMN), and Covalon Technologies (COV).

Novoheart (CVE:NVH) and Ceapro (CVE:CZO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Novoheart and Ceapro, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novoheart0000N/A
Ceapro0000N/A

Profitability

This table compares Novoheart and Ceapro's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NovoheartN/AN/AN/A
CeaproN/AN/AN/A

Valuation and Earnings

This table compares Novoheart and Ceapro's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoheartC$423,500.00236.08C$-7,168,358.00C($0.04)-13.95
CeaproC$16.14 million3.46C$2.56 millionC$0.0321.82

Ceapro has higher revenue and earnings than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than Ceapro, indicating that it is currently the more affordable of the two stocks.

Summary

Ceapro beats Novoheart on 4 of the 5 factors compared between the two stocks.

Microbix Biosystems (TSE:MBX) and Ceapro (CVE:CZO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Microbix Biosystems and Ceapro, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Microbix Biosystems0000N/A
Ceapro0000N/A

Profitability

This table compares Microbix Biosystems and Ceapro's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Microbix BiosystemsN/AN/AN/A
CeaproN/AN/AN/A

Valuation & Earnings

This table compares Microbix Biosystems and Ceapro's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Microbix BiosystemsC$11.64 million5.64C$-5,581,797.00C($0.05)-11.76
CeaproC$16.14 million3.46C$2.56 millionC$0.0321.82

Ceapro has higher revenue and earnings than Microbix Biosystems. Microbix Biosystems is trading at a lower price-to-earnings ratio than Ceapro, indicating that it is currently the more affordable of the two stocks.

Summary

Ceapro beats Microbix Biosystems on 4 of the 5 factors compared between the two stocks.

Ceapro (CVE:CZO) and Pediapharm (CVE:PDP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, analyst recommendations, profitability, earnings and risk.

Earnings and Valuation

This table compares Ceapro and Pediapharm's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CeaproC$16.14 million3.46C$2.56 millionC$0.0321.82
PediapharmC$11.16 million5.95C$-16,147,162.00C($0.07)-4.11

Ceapro has higher revenue and earnings than Pediapharm. Pediapharm is trading at a lower price-to-earnings ratio than Ceapro, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Ceapro and Pediapharm, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ceapro0000N/A
Pediapharm0000N/A

Profitability

This table compares Ceapro and Pediapharm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CeaproN/AN/AN/A
PediapharmN/AN/AN/A

Summary

Ceapro beats Pediapharm on 4 of the 5 factors compared between the two stocks.

Ceapro (CVE:CZO) and Sirona Biochem (CVE:SBM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.

Profitability

This table compares Ceapro and Sirona Biochem's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CeaproN/AN/AN/A
Sirona BiochemN/AN/AN/A

Earnings and Valuation

This table compares Ceapro and Sirona Biochem's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CeaproC$16.14 million3.46C$2.56 millionC$0.0321.82
Sirona BiochemC$123,870.00661.64C$-2,959,580.00C($0.01)-27.69

Ceapro has higher revenue and earnings than Sirona Biochem. Sirona Biochem is trading at a lower price-to-earnings ratio than Ceapro, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Ceapro and Sirona Biochem, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ceapro0000N/A
Sirona Biochem0000N/A

Summary

Ceapro beats Sirona Biochem on 4 of the 5 factors compared between the two stocks.

Ceapro (CVE:CZO) and ProMIS Neurosciences (TSE:PMN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current recommendations for Ceapro and ProMIS Neurosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ceapro0000N/A
ProMIS Neurosciences0000N/A

Profitability

This table compares Ceapro and ProMIS Neurosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CeaproN/AN/AN/A
ProMIS NeurosciencesN/AN/AN/A

Valuation & Earnings

This table compares Ceapro and ProMIS Neurosciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CeaproC$16.14 million3.46C$2.56 millionC$0.0321.82
ProMIS NeurosciencesC$1,787.0030,817.57C$-6,119,000.00C($0.02)-9.00

Ceapro has higher revenue and earnings than ProMIS Neurosciences. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Ceapro, indicating that it is currently the more affordable of the two stocks.

Summary

Ceapro beats ProMIS Neurosciences on 4 of the 5 factors compared between the two stocks.

Ceapro (CVE:CZO) and Covalon Technologies (CVE:COV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.

Profitability

This table compares Ceapro and Covalon Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CeaproN/AN/AN/A
Covalon TechnologiesN/AN/AN/A

Earnings and Valuation

This table compares Ceapro and Covalon Technologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CeaproC$16.14 million3.46C$2.56 millionC$0.0321.82
Covalon TechnologiesC$23.84 million1.68C$-6,144,922.00C($0.24)-6.51

Ceapro has higher earnings, but lower revenue than Covalon Technologies. Covalon Technologies is trading at a lower price-to-earnings ratio than Ceapro, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Ceapro and Covalon Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ceapro0000N/A
Covalon Technologies0000N/A

Summary

Ceapro beats Covalon Technologies on 4 of the 5 factors compared between the two stocks.


Ceapro Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
NVH
Novoheart
0.5$0.53-1.9%C$79.23 millionC$423,500.00-13.95
MBX
Microbix Biosystems
0.9$0.60-1.7%C$66.76 millionC$11.64 million-11.76News Coverage
PDP
Pediapharm
0.5$0.30-1.7%C$66.36 millionC$11.16 million-4.11
SBM
Sirona Biochem
0.5$0.36-4.2%C$58.80 millionC$123,870.00-27.69
PMN
ProMIS Neurosciences
0.5$0.18-0.0%C$55.07 millionC$1,787.00-9.00News Coverage
Gap Down
COV
Covalon Technologies
0.6$1.55-3.2%C$37.44 millionC$23.84 million-6.51
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.25-2.0%C$34.02 millionC$13.02 million-0.36
IGX
IntelGenx Technologies
0.9$0.53-1.9%C$30.87 millionC$1.54 million-6.54
QPT
Quest PharmaTech
0.8$0.11-4.8%C$21.76 millionC$38,871.000.16High Trading Volume
Gap Up
CTX
Crescita Therapeutics
0.6$0.80-6.3%C$16.52 millionC$15.64 million400.00
KNE
Kane Biotech
0.4$0.20-2.6%C$14.12 millionC$1.34 million-5.57High Trading Volume
GSD
Devonian Health Group
0.5$0.28-7.1%C$13.96 millionC$1.59 million-5.83Gap Down
PAS
Pascal Biosciences
0.6$0.08-6.3%C$12.70 millionN/A-3.64Gap Up
NSP
Naturally Splendid Enterprises
0.6$0.06-0.0%C$11.06 millionC$2.03 million-1.40
MPH
Medicure
0.7$1.63-1.2%C$10.80 millionC$12.71 million-1.05Gap Up
BTI
Bioasis Technologies
0.7$0.33-3.0%C$10.16 millionC$4.12 million30.00Gap Down
HEM
Hemostemix
0.6$0.34-1.5%C$9.07 millionN/A-2.02Gap Down
ICO
iCo Therapeutics
0.5$0.11-0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.38-2.6%C$6.94 millionC$5.60 million7.04
IOT
Innovotech
0.8$0.17-5.9%C$6.52 millionC$1.04 million85.00Gap Down
BCT
BriaCell Therapeutics
0.5$3.69-3.5%C$4.48 millionN/A-1.19
RVV
Revive Therapeutics
0.5$0.08-12.5%C$3.62 millionN/A-3.64High Trading Volume
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04-71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03-16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01-0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3$46.83-1.6%C$0.00C$267.59 million51.46
LTY
Liberty Biopharma
0.6$2.00-100.0%C$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
SCYB
Scythian Biosciences
0.5$3.49-6.3%C$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32-5.3%C$0.00N/A0.00News Coverage
Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.